type 2 diabetes-mellitus-mild cognitive impairment
Conditions
Interventions
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Aged 45 to 75 years; gender is not limited; the diagnosis of Diabetes Mellitus meets the criteria established by WH0 in 1999, and the subject is clearly diagnosed as type 2 Diabetes Mellitus. (2) The main complaint of memory impairment is confirmed by others. (3) Clinical evaluation confirmed the existence of cognitive impairment, MOCA 18 points, the primary school group > 21 points, the junior high school or above group > 24 points indicated that the cognitive function is preserved. (6) Activities of daily living are in good condition or have very minor damage, such as instrumental activities of daily living (IADL) score is greater than or equal to 16 points. (7) Have sufficient visual and auditory resolution to undergo neuropsychological testing. (8) There is no evidence of infection, infarction or other focal injury in the CT or MRI scan within 12 months prior to MCI screening, and there is no related clinical symptoms, but lacunar infarction in a non-critical brain region is allowed and it is not considered to affect the cognitive impairment of the subjects; the Hachinski Ischemia Scale (HIS) score is less than or equal to 4 points. Subjects voluntarily joined the study and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Acute complications such as diabetic ketoacidosis in the past 3 months; (2) History of severe heart, lung and kidney failure; (3) suffering from depression within the past 2 years, the General Hospital Anxiety/Depression Sex Measurement Form (SDS) score >= 50 points. (4) History of alcohol, drug abuse or dependence within the past 2 years. (5) The following drugs have been used within 1 month before cognitive impairment screening: anti-Parkinson's disease drugs, short acting anti-anxiety agents, sedative drugs, anti-pain drugs, drugs with obvious cholinergic or anti cholinergic adverse reactions. (6) Patients have no complete datas.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FBG;PBG;HBA1C;FINS;F-CP;Montreal Cognitive Assessment Scale;Mini-mental state examination scale;Clinical dementia grading scale;Instrumental activities of daily living scale;Anxiety self-rating scale;Depression self-rating scale;Hachinski ischemic index scale;TCM syndrome type questionnaire;Patients miRNA; | — |
Countries
China
Contacts
Public ContactWei Jun-Ping
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Outcome results
None listed